Latent

Latent (operating as Latent Health, latenthealth.com) is a San Francisco-based clinical-AI company building an enterprise platform for medication access and hospital pharmacy operations. Its stated purpose is to remove the manual work between a physician's order and a patient starting therapy by bringing clinical intelligence into the patient record and automating the steps required to obtain approval, fill, and maintain prescriptions.

The product is organized around four functional areas described on the company website: Identify (finding eligible patients), Access (improving approval rates for prior authorizations), Capture (retaining specialty scripts within the health system), and Engage (patient follow-up and adherence support). Underlying these is what the company calls a clinical agentic engine, or Clinical Reasoning Engine, that reasons over patient data, interprets drug coverage criteria, extracts supporting evidence, auto-fills and submits payer forms, and coordinates workflows across the EHR, payers, pharmacies, and patients. Earlier positioning on its Y Combinator profile described the company as building medical language models to automate healthcare operations, with a flagship product that streamlines authorizations for life-saving drugs by analyzing EHR records and surfacing the most relevant data.

Reported customers include Yale New Haven Health, Ochsner Health, MetroHealth, UCI, Vanderbilt Health, Mount Sinai Health System, Henry Ford Health System, UCSF Health and UCLA Health. Company-published outcome figures cover copay assistance accessed, pharmacist time returned per appeal, prior-authorization throughput, and labor cost avoidance; these are self-reported and, in the platform illustrations, partly labeled as sample data.

Founding story

Latent was co-founded by Sriram (Sri) Somasundaram and Rishabh (Rish) Jain, who are described in the April 2026 funding coverage as co-CEOs. Y Combinator's profile describes Jain as a repeat founder and Somasundaram as having researched molecular binding patterns underlying adaptive immunity and built deep reinforcement learning robots at Stanford, with publications at ICML, ICLR and Nature, before operationalizing language models for large financial institutions on the founding team of Hebbia. The company was founded in 2022 and went through Y Combinator's Winter 2023 batch, with Aaron Epstein as primary partner.

Business model

Latent sells enterprise software to health systems, positioning itself as infrastructure for centralized medication access and pharmacy operations. The platform is deployed inside provider organizations, integrates natively with EHRs, and is marketed on operational outcomes such as increased prior-authorization throughput per staff member, labor cost avoidance, and net-new specialty pharmacy revenue captured without adding headcount.

Sources do not disclose pricing or contract structure. Y Combinator's profile states the company has signed enterprise contracts with some of the largest US health systems, indicating a B2B enterprise contracting model with health systems as the paying customers.

Traction

Press coverage in 2026 reports more than 45 health systems using the platform and more than 2 million patients served annually; the company website claims 50+ health systems. Named customers include Yale New Haven Health, Ochsner Health, MetroHealth, UCI, Vanderbilt Health, Mount Sinai Health System, Henry Ford Health System, UCSF Health and UCLA Health. Company-reported outcomes include $50M in copay assistance accessed, 109% higher prior-authorization throughput per team member, review time reduced from 18 to 3.5 minutes, 23.4 of 30.6 minutes per appeal returned to pharmacists, and $300K+ in annual labor cost avoided at a named system. Team size is listed at 50, with open engineering and design roles in San Francisco.

Latest developments

In March 2026 the company was the subject of a Forbes-linked feature referenced on its Y Combinator page describing a $600 million AI startup speeding up paperwork so patients get drugs faster. FinSMEs reported an $80M Series A on 19 March 2026 co-led by Spark Capital and Transformation Capital with participation from Conviction, McKesson Ventures, General Catalyst and Y Combinator, and published a second, near-identical report on 8 April 2026 describing the round as led by the same two firms; the two reports may describe the same transaction. Proceeds are earmarked for expanding the health system footprint, deepening the platform across hospitals, payers, pharmacies and patients, investing in reliability and trust, and scaling the team. The company also promotes a 2026 KLAS Emerging Company Spotlight score of 94.5.